Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction

NCT07325955 | Completed DMC

• 2 other identifiers: TMZAMI002SF2020-2-5012
• Study Type: observational
• Target: 194
• Locations: 1 country
• Sites: 1

Brief Summary

Trimetazidine is a agent promoting glucose utilization by limiting fatty-acid oxidation.Trimetazidine could improve cardiac function in patients with ischemic heart disease. We aimed to explore effect of Trimetazidine on final myocardial fibrosis for patients with ST-elevation myocardial infarction (STEMI) in real world clinical practice. In this observational study, we investigated the effect of long-term treatment with trimetazidine on the final extent of myocardial fibrosis measured by cardiac magnetic resonance 6 months after infarction in real world clinical practice.

Conditions

ST Elevation Myocardial Infarction (STEMI)

Keywords

Acute myocardial infarction; Trimetazidine; Metabolic therapy

Outcome Measures

Primary Outcomes (1)

• myocardial fibrosis measured by cardiac magnetic resonance imaging

  Delayed enhancement of cardiac magnetic resonance imaging showed the myocardial fibrosis after infarction

  6 months after infarction

Study Arms (2)

Trimetazidine treatment group

Patients with trimetazidine treatment

Control group

Patients without Trimetazidine treatment

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Study participants were recruited from the Chinese PLA general hospital in Beijing

You may qualify if:

• Diagnosed STEMI patients within one day after reperfusion threapy; Have performed the primary PCI procedure; Sign the informed consent form for this cohort study

You may not qualify if:

• Mechanical complications; Cardiogenic shock; Malignant tumors, severe infection, hepatic or renal failure, respiratory failure, or other short-term progressive diseases

Sponsors & Collaborators

• Chinese PLA General Hospital: lead

Study Sites (1)

Chinese PLA general hospital

Beijing, Haidian, 100853, China

Location

Related Publications (10)

• Demirelli S, Karakelleoglu S, Gundogdu F, Tas MH, Kaya A, Duman H, Degirmenci H, Hamur H, Simsek Z. The Impact of Trimetazidine Treatment on Left Ventricular Functions and Plasma Brain Natriuretic Peptide Levels in Patients with Non-ST Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Korean Circ J. 2013 Jul;43(7):462-7. doi: 10.4070/kcj.2013.43.7.462. Epub 2013 Jul 31.

  PMID: 23964292 RESULT

• Shehata M. Cardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis. Cardiol Res. 2014 Apr;5(2):58-67. doi: 10.14740/cr330w. Epub 2014 May 15.

  PMID: 28392876 RESULT

• Li R, Tang X, Jing Q, Wang Q, Yang M, Han X, Zhao J, Yu X. The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI. Am J Emerg Med. 2017 Nov;35(11):1657-1661. doi: 10.1016/j.ajem.2017.05.024. Epub 2017 May 23.

  PMID: 28587952 RESULT

• Li Y, Wang D, Hu C, Zhang P, Zhang D, Qin S. Efficacy and Safety of Adjunctive Trimetazidine Therapy for Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. Cardiology. 2016;135(3):188-195. doi: 10.1159/000446640. Epub 2016 Jul 15.

  PMID: 27415810 RESULT

• Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM. The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol. 2008 Oct;6(4):282-91. doi: 10.2174/157016108785909788.

  PMID: 18855716 RESULT

• El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5(4):271-8. doi: 10.2165/00129784-200505040-00006.

  PMID: 15984909 RESULT

• Kim JS, Kim CH, Chun KJ, Kim JH, Park YH, Kim J, Choi JH, Lee SH, Kim EJ, Yu DG, Ahn EY, Jeong MH. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry. Clin Res Cardiol. 2013 Dec;102(12):915-22. doi: 10.1007/s00392-013-0611-0. Epub 2013 Aug 28.

  PMID: 23982468 RESULT

• Bonello L, Sbragia P, Amabile N, Com O, Pierre SV, Levy S, Paganelli F. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart. 2007 Jun;93(6):703-7. doi: 10.1136/hrt.2006.107524. Epub 2007 May 8.

  PMID: 17488771 RESULT

• Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006 Sep 5;48(5):992-8. doi: 10.1016/j.jacc.2006.03.060. Epub 2006 Aug 17.

  PMID: 16949492 RESULT

• Singh D, Oladimeji-Salami J, Akindele AJ. New insights on pharmacological and therapeutic potentials of trimetazidine beyond anti-anginal drug: A comprehensive review. Eur J Pharmacol. 2024 Dec 15;985:177062. doi: 10.1016/j.ejphar.2024.177062. Epub 2024 Oct 19.

  PMID: 39427862 RESULT

MeSH Terms

Conditions

ST Elevation Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial Infarction; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: December 25, 2025
• First Posted: January 8, 2026
• Study Start: October 1, 2020
• Primary Completion: July 1, 2024
• Study Completion: December 1, 2024
• Last Updated: January 8, 2026

Record last verified: 2025-12

Locations

CN (1)